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Abstract: Background: Dietary supplementation with leucine and fish oil rich in omega-3 fatty
acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) has previously been shown
to reduce cachexia-related outcomes in C26 tumour-bearing mice. To further explore associated
processes and mechanisms we investigated changes in plasma Ca2+ levels, the involvement of
parathyroid hormone related protein (PTHrP), and its possible interactions with cyclooxygenase 2
(COX-2). Methods: CD2F1 mice were subcutaneously inoculated with C26 adenocarcinoma cells
or sham treated and divided in: (1) controls, (2) tumour-bearing controls, and (3) tumour-bearing
receiving experimental diets. After 20 days, body and organ masses and total plasma Ca2+ levels were
determined. Furthermore, effects of DHA, EPA and leucine on production of PTHrP were studied
in cultured C26 cells. Results: The combination of leucine and fish oil reduced tumour-associated
hypercalcemia. Plasma Ca2+ levels negatively correlated with carcass mass and multiple organ masses.
DHA was able to reduce PTHrP production by C26 cells in vitro. Results indicate that this effect
occurred independently of COX-2 inhibition. Conclusion: Our results suggest that cancer-related
hypercalcemia may be ameliorated by a nutritional intervention rich in leucine and fish oil. The effect
of fish oil possibly relates to a DHA-induced reduction of PTHrP excretion by the tumour.
Keywords: hypercalcemia; PTHrP; cachexia; fish oil; leucine
1. Introduction
Cancer-related hypercalcemia is seen in up to 30% of patients with malignancies [1]. Very often,
this is accompanied by increased bone resorption [2]. Calcium plays a vital role in many different
physiological functions, for example in the contraction of all muscle cell types and neuronal signalling.
In healthy individuals, the plasma concentration of calcium is tightly regulated by the interplay of
parathyroid hormone (PTH), vitamin D and calcitonin [2]. In patients with malignant disorders,
calcium balance is often disrupted, reflected by elevated calcium plasma levels [1]. Calcium is partly
bound to albumin and its plasma levels are either expressed as albumin corrected levels (common in
clinical practice) or as total Ca2+ levels (free + bound). Hypercalcemia is defined in patients as mild
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for levels between 10.5 and 11.9 mg/dL (2.6–2.9 mmol/L), as moderate between 12 and 13.9 mg/dL
(3.0–3.4 mmol/L), and as severe above 14 mg/dL (3.5 mmol/L) serum total Ca2+ [1,3]. The main cause
of malignancy-related hypercalcemia is an imbalance in bone formation and resorption [3].
The most prevalent clinical symptoms with hypercalcemia relate to neurologic, psychiatric,
gastrointestinal, cardiovascular and renal abnormalities [2–4]. Neurologic and psychiatric symptoms
include fatigue, lethargy, musculoskeletal pain, depression, and even coma. Reduced motility of the
gastrointestinal tract can cause constipation and reduced appetite. Cardiovascular symptoms include
cardiac arrhythmias and hypertension. Moreover, renal failure is frequently present in hypercalcemia.
Symptoms of hypercalcemia are frequently seen in cancer patients. For example, in multiple myeloma
patients, serum calcium levels were an independent predictor of quality of life, fatigue and physical
functioning [5].
There are three proposed mechanisms by which malignancies can affect the balance between
Ca incorporation in bone and its resorption [2]. The first is associated with increased degradation of
bone by osteoclasts, which become activated by factors secreted by metastases or primary tumours in
or close to the bone. A second mechanism involves increased levels of inflammatory mediators like
interleukin 6 (IL-6), prostaglandin E2 (PGE-2), and of PTH-related protein (PTHrP), which directly
cause increased breakdown of bone. A third possibility is based on the connection to coexisting
primary hyperparathyroidism. Of these three proposed mechanisms, the one involving PTHrP secreted
by the tumour is considered the most prominent and responsible for 80% of all malignancy-related
hypercalcemia patients [4].
PTHrP is a protein between 139 and 173 amino acids in size. Its N-terminal shows homology
with PTH. PTHrP is produced in low concentrations by practically all tissues. PTHrP produced by
the tumour can bind and activate the PTH receptor leading to increased bone demineralization and
increased renal reabsorption of calcium [6]. Both these processes contribute to the increase in plasma
calcium levels. Bone resorption can lead to TGFβ release, which in turn stimulates PTHrP secretion by
tumour cells, thus initiating a vicious cycle [6,7]. The elevation of PTHrP in C26 adenocarcinoma cells
has been reported to depend on an increase in cyclooxygenase 2 (COX-2) activity, which in parallel
also results in an elevated PGE-2 production [8]. Apart from its effects on bone calcium turnover,
PTHrP also directly stimulates muscle wasting and adipose tissue browning [9]. Possibly related to
this, serum PTHrP levels were found to be predictive of weight loss in cancer patients independently
of hypercalcemia, inflammation and tumour burden [10]. Together, these findings suggest an overlap
between features of cancer cachexia and malignancy-related hypercalcemia, two clinically relevant
paraneoplastic syndromes. In order to investigate whether this overlap would also apply to possible
intervention strategies for cachexia, the present study was initiated. This study investigated the effects
of a diet enriched in leucine, protein and fish oil on PTHrP related changes of plasma Ca levels in a
tumour-induced cachexia model. In the same animals, we previously showed significant improvement
of cachexia-related outcomes in those mice that had received such specific nutritional combination
(SNC) [11]. Starting from the hypothesis that supplementation of fish oil and leucine might also reduce
plasma Ca2+ levels in tumour-bearing animals, we further investigated the involvement of PTHrP
and COX-2 in the regulation of Ca2+ levels by docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA), respectively. To this end, we performed a series of in vitro experiments with C26 cells.
2. Results
2.1. Effect of Leucine and Fish Oil in Vivo in Experiment A,B
2.1.1. Calcium Levels and Their Correlation with Carcass Mass, Organ Masses and EDL Muscle
Function.
We determined whether cachexia-associated outcomes might be related to plasma Ca2+ levels.
As previously published, carcass mass was decreased, as seen in Figure 1A,C, in tumour-bearing
(TB) mice, compared to the carcass mass of control mice which was improved to a certain extent by
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supplementation of fish oil and leucine or the SNC [11]. Our additional analysis showed a two-fold
increase in plasma Ca2+ levels in the tumour-bearing animals as seen in Figure 1. The combination
of leucine and fish oil was able to significantly reduce the tumour-induced hypercalcemia, whereas
the individual components could not reduce hypercalcemia as seen in Experiment A, Figure 1B.
Similar reductions in plasma Ca2+ levels were found in animals supplemented with the complete SNC
containing high protein, leucine, fish oil and oligosaccharides as seen in Experiment B, Figure 1D.
Moreover, plasma Ca2+ levels were negatively correlated with carcass weight and with multiple
organ masses as seen in Figure 1E and Table 1. Muscle function of mEDL was determined ex vivo
in an organ bath. For all frequencies at which tetanus could be obtained (>83 Hz), muscle function
parameters (maximal force, maximal contraction velocity and maximal relaxation velocity), correlated
negatively with calcium levels (R below −0.7 and p < 0.05) as seen in Table 2. When the muscle
function parameters, maximal force, maximal contraction velocity and maximal relaxation velocity
were corrected for muscle mass, negative correlations remained, though R values were less (between
−0.35 and −0.7), and significant levels were obtained for all parameters for frequencies ≥100 Hz.
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Figure 1. Effect of leucine (LEU), fish oil (FO) and a combination of leucine and fish oil on carcass 
weight and plasma Ca2+ levels (A,B); and effect of a specific nutritional combination (SNC) containing 
added fish oil and leucine on carcass weight and plasma Ca2+ levels (C,D). Data represent mean ± 
SEM. Correlation between carcass weight and plasma Ca2+ levels (Pearson r = −0.6684 [Experiment A] 
and −0.8097 [Experiment B], both with p < 0.0001) (E). *, ** and *** represent significant differences 
with tumour-bearing (TB) group (respectively, p < 0.05, p < 0.01 and p < 0.001). 
2.1.2. Plasma PGE-2 and Tumour PTHrP 
Inflammatory mediators like PGE-2 and PTHrP have been reported to play a potential role in 
the onset of hypercalcemia. Plasma PGE-2 levels were significantly increased in TB compared to 
control mice as seen in Figure 2B. This increase was reduced upon supplementation of fish oil either 
with or without added leucine. Plasma Ca2+ and PGE-2 levels correlated significantly (Pearson r = 
0.6062 with p < 0.0001) as seen in Figure 2F. Tumour PTHrP levels were significantly lower in TB 
animals that had received diets enriched with fish oil and leucine compared to TB animals without 
supplementation as seen in Figure 2C. Tumour PTHrP levels did not correlate with plasma Ca2+ levels. 
Figure 1. Effect of leucine (LEU), fish oil (FO) and a combination of leucine and fish oil on carcass
weight and plasma Ca2+ levels (A,B); and effect of a specific nutritional combination (SNC) containing
added fish oil and leucine on carcass weight and plasma Ca2+ levels (C,D). Data represent mean ±
SEM. Correlation between carcass weight and plasma Ca2+ levels (Pearson r = −0.6684 [Experiment A]
and −0.8097 [Experiment B], both with p < 0.0001) (E). *, ** and *** represent significant differences
with tumour-bearing (TB) group (respectively, p < 0.05, p < 0.01 and p < 0.001).
2.1.2. Plasma PGE-2 and Tumour PTHrP
Inflammatory mediators like PGE-2 and PTHrP have been reported to play a potential role in the
onset of hypercalcemia. Plasma PGE-2 levels were significantly increased in TB compared to control
mice as seen in Figure 2B. This increase was reduced upon supplementation of fish oil either with or
without added leucine. Plasma Ca2+ and PGE-2 levels correlated significantly (Pearson r = 0.6062 with
p < 0.0001) as seen in Figure 2F. Tumour PTHrP levels were significantly lower in TB animals that had
received diets enriched with fish oil and leucine compared to TB animals without supplementation as
seen in Figure 2C. Tumour PTHrP levels did not correlate with plasma Ca2+ levels. However, it should
be noted that there were no PTHrP levels determined in control animals since they have no tumour.
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Kidney −0.409 ** −0.635 ** 
Liver −0.480 ** −0.527 ** 
Intestine 0.243 * 0.141 
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Heart  −0.338 ** −0.743 ** 
Lung 0.355 ** 0.098 
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Table 1. Correlation of plasma calcium levels and organ weights. * and ** represent significant Pearson
correlation coefficients of Experiment A (combination vs. separate compounds and controls) and B
(total product vs. controls) (respectively, p < 0.05 and p < 0.01).
Pearson Correlation Coefficients with Plasma Ca2+ Levels Experiment A Experiment B
M. tib alis anterior −0.640 ** −0.705 **
M. extensor digitorum longus −0.498 ** −0.628 **
M. soleus −0.579 ** −0.603 **
M. gastrocnemius −0.623 ** −0.772 **
Epididymal fat pad −0.659 ** −0.783 **
Spleen 0.552 ** 0.695 **
Kidney −0.409 ** −0.635 **
Liver −0.480 ** −0.527 **
Intestine 0.243 * 0.141
Thymus −0.701 ** −0.561 **
Heart −0.338 ** −0.743 **
Lung 0.355 ** 0.098
Table 2. Correlation of plasma calcium levels and muscle function of Experiment B (total product vs.
controls). *, ** and # represent significant Pearson correlation coefficient intervals of parameters of
EDL muscle function at the frequencies 83 till 167 Hz (* = p < 0.05 and ** = p < 0.01 for all frequencies
measured; and # = p < 0.01 for the frequencies ≥100 Hz).
Pearson Correlation Coefficients with Plasma Ca2+ Levels R Interval
Maximal force −0.81 to −0.83 **
Maximum contraction velocity −0.74 to −0.82 **
Maximum relaxation velocity −0.78 to −0.85 **
Maximal force corrected for muscle mass −0.47 to −0.53 *
Maximal contraction velocity corrected for muscle mass −0.42 to −0.66 *
Maximal relaxation velocity corrected for muscle mass −0.38 to −0.60 #
2.2. Effect of Leucine and Fish Oil in Vitro in Experiment C–E
2.2.1. Supplementation of C26 Cells with Nutritional Components used in Vivo in Experiment C,D
To determine possible mechanisms behind the effects of the nutritional supplementation with
leucine and fish oil in C26 mice, a sequence of in vitro experiments was performed. In Experiment C,
small numbers of C26 cells were incubated with omega-3 fatty acids EPA or DHA, or leucine added
to the medium and PTHrP production was measured. Experiments showed that DHA and EPA at a
concentration of 50 µM (DHA), 100 µM (DHA) and 100 µM (EPA) significantly reduced C26 PTHrP
production by 36%, 39% and 35%, respectively, as seen in Figure 3A,B. Leucine had no effect on PTHrP
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production in vitro as seen in Figure 3C. None of the components had any effect on viability or toxicity
in the concentrations tested as seen in Figure S1. Given that DHA and EPA were found to be the most
potent in reducing PTHrP, these were incorporated into the next experiments. To test the consistency of
the findings and to mimic the effects of the potent components DHA and EPA on the tumour, we tested
the effects on cells with a higher confluence in Experiment D. The effect of EPA was no longer present.
The effect of DHA, however, was reproducible in these confluent cells with reductions of 32% and 34%
at 50 µM DHA and 100 µM DHA, respectively, as seen in Figure 3D,E.
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upon stimulation of COX-2 [8]. Therefore, to further elucidate the possible mode of action of DHA, 
we determined whether COX-2 was involved in the PTHrP reducing effects of DHA in Experiment 
E. This was done by measuring PGE-2 production upon incubation of C26 cells with DHA. As a 
positive control, the specific COX-2 inhibitor celecoxib (CXB) was used. Results showed that DHA 
was not able to reduce PGE-2 production in C26 cells where CXB reduced PGE-2 levels with 73% at 
a dose of 0.01 μM, as seen in Figure 4A,B. Moreover, PTHrP production of C26 cells was not reduced 
when COX-2 activity was inhibited by incubation with CXB as seen in Figure 4C. This indicates that 
the effect of DHA was possibly not mediated via the enzyme COX-2. In Experiment D,E, none of the 
conditions resulted in an increased toxicity, as measured by LDH as seen in Figure S2. 
Figure 3. Effect of supplementation of C26 cells with docosahexaenoic acid (DHA) (A,D);
eicosapentaenoic acid (EPA) (B,E); and leucine (LEU) (C) on PTHrP levels on low (A–C); and high (D,E)
number of cells. Data represent mean ± SEM. *, ** and *** represent significant differences with vehicle
control (respectively, p < 0.05, p < 0.01 and p < 0.001).
2.2.2. Possible Involvement of COX-2 in the Effect of Fish Oil in Experiment E
DHA is known to reduce COX-2 activity [12], and PTHrP production is known to be stimulated
upon stimulation of COX-2 [8]. Therefore, to further elucidate the possible mode of action of DHA,
we determined whether COX-2 was involved in t e PTHrP reducing effects of DHA in Experiment E.
This was done by measuring PGE-2 production upon incubation of C26 cells with DHA. As a positive
control, the specific COX-2 inhibitor celecoxib (CXB) was used. Results showed that DHA was not able
to reduce PGE-2 production in C26 cells where CXB reduced PGE-2 levels with 73% at a dose of 0.01
µM, as seen in Figure 4A,B. Moreover, PTHrP production of 26 cells was not reduced when COX-2
activity was inhibited by incubation with CXB as seen in Figure 4C. This indicates that the effect of
DHA was possibly not mediated via the enzyme COX-2. In Experiment D,E, none of the conditions
resulted in an increased toxicity, as easured by LDH as seen in Figure S2.
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3. Materials and Methods
3.1. In Vivo Experiments
3.1.1. Animals and Experimental Diets
For the present study, we started our research by analysing archived materials from a previous
in vivo study, which made it possible to limit new animal research. That study investigated the effects
of a specific nutritional combination of oligosaccharides, high protein, leucine, and fish oil on muscle
and daily activity [11]. Experimental procedures have been described in detail in the previous paper.
Briefly, male CD2F1 mice aged 6–7 weeks were divided into weight-matched groups: (1) control
mice receiving control diet high in protein (C), (2) tumour-bearing mice receiving the same control
diet (TB), and (3) tumour-bearing mice receiving experimental diets. In Experiment A, the effect of
additional leucine (LEU) and fish oil (FO) on top of the high protein diet was tested. In Experiment B,
the specific nutritional combination (SNC) of oligosaccharides, high protein, leucine and fish oil was
used. All diets used in the different experiments were iso-caloric, by exchanging additional protein
or fat with carbohydrates. In Experiment A, AIN93-M, supplied as pellets, was used as control diet,
and for the experimental groups the specific nutritional components were added. In Experiment B,
a more human-like control diet was used which was iso-caloric and isonitrogenous to the diet used
in Experiment A. Both the control diet as the iso-caloric experimental SNC in Experiment B were
supplied as dough. Experimental procedures were approved by the Animal Ethics Committee (DEC
consult, Bilthoven, The Netherlands) and complied with the principles of good laboratory animal care
(DEC/DAN100).
3.1.2. Experimental Protocol
Murine C26 denocarcinoma cells were cultured and inoculated as reported previously [11,13].
Briefly, under general anaesthesia (isoflurane/N2O/O2), tumour cells (5 × 105 cells in 0.2 mL) were
inoculated subcutaneously into the right inguinal flank of the mice. Control (C) animals received a
sham injection with 0.2 mL HBSS. Animals were weighed and anaesthetized (isoflurane/N2O/O2) at
day 20 after tumour inoculation. Skeletal muscle and internal organs were dissected and weighed.
Carcass mass was calculated by subtracting tumour mass from body mass. Ex vivo EDL muscle
function was measured at different frequencies ranging from 20 to 167 Hz. Tetanus was reached at
frequencies ≥83 Hz.
3.1.3. Plasma PGE-2 and Tumour PTHrP in Experiment A
In animals from Experi ent A, plasma PGE-2 was measured using a commercial anti-PGE-2 rabbit
polyclonal antibody-based direct enzyme immunoassay (Oxford Biomedical Research, Oxford, MI,
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USA) according to the manufacturer’s protocol. PTHrP levels in the tumour of animals in Experiment
A were measured using a quantitative PTHrP enzyme-linked immunosorbent (ELISA) assay kit (USCN
Life Science Inc., Wuhan, Hubei, China) according to the manufacturer’s protocol. PTHrP levels were
expressed as amount per milligram of protein as determined using a PierceTM BCA protein kit (Thermo
Fisher Scientific, Rockford, Illinois, USA). Unfortunately, the amount of stored plasma material was
insufficient to determine plasma PTHrP levels.
3.1.4. Plasma Calcium in Experiment A,B
To investigate if the elevation of calcium levels was linked to body and organ masses and
PGE-2 levels, total plasma Ca2+ levels (free calcium + calcium bound to albumin) were determined
calorimetrically at the Clinical Chemistry Laboratory Hospital Reinier de Graaf (Delft, the Netherlands).
3.2. In Vitro Experiments
To determine possible underlying mechanisms, we set up a series of in vitro experiments. First,
we tested the main components present in the diets used in the mouse studies on a low number of
tumour cells, as seen in Experiment C. As a control, viability and toxicity assays were performed to rule
out potentially toxic effects of components in the concentrations tested. Subsequently, we continued
with the most potent compounds on a larger number of cells, as seen in Experiment D, to test their
potency in situations more resembling the in vivo situation (i.e., the tumour consists of a very large
number of cells). Lastly, we examined a possible mechanism of action of the most potent compound,
as seen in Experiment E, by assessing the possible involvement of COX-2 by using a specific COX-2
inhibitor. In Experiment D,E, only toxicity assays were performed.
3.2.1. Culture of Murine C26 Cells
All in vitro experiments were performed using murine C26 tumour cells (American Type Culture
Collection; ATCC, Teddington, UK). Cells were cultured in DMEM with 10% heat-inactivated foetal
bovine serum at 37 ◦C in a 5% CO2 humidified air atmosphere. For supplementation in Experiment
C,D,E, cells were seeded in a 24-wells plate. For Experiment C, 25,000 cells were seeded leading to a
confluence of 10–20% after 24h with ample cell–cell contact. For Experiment D,E, 250,000 cells were
seeded leading to a confluence of 80–90% after 24h with a high degree of cell–cell contact.
3.2.2. PTHrP and PGE-2 Production upon Supplementation of C26 cells with DHA, EPA, Leucine
and CXB
After 24 h of incubation, culture medium from each well was removed and C26 cells were
supplemented with test compound or vehicle control. Supplementation for 24h was performed with
different concentrations of either docosahexaenoic acid (DHA, 22:6n-3; Sigma-Aldrich, Sigma-Aldrich
Chemie GmbH, Schnelldorf, Germany), eicosapentaenoic acid (EPA, 20:5n-3; Sigma-Aldrich Chemie
GmbH), leucine (Sigma-Aldrich Chemie GmbH), or celecoxib (CXB, Sigma-Aldrich Chemie GmbH).
Ethanol was used as solvent forω-3 PUFAs (DHA and EPA), DMSO was used as solvent for CXB and
leucine was dissolved in PBS. In all cases, final ethanol/DMSO concentration never exceeded 0.1% v/v.
All experiments were performed at least three times, and each condition was done in duplicate or
triplicate. After 24h of supplementation, supernatant was removed for analysis of PTHrP and PGE-2.
PTHrP production in C26 cell supernatant was measured using a commercially available ELISA (USCN
Life Science Inc., Wuhan, Hubei, China) according to the manufacturer’s protocol. PGE-2 production
was measured using a commercially available monoclonal ELISA kit (Cayman chemical, Ann Arbor,
Michigan, USA).
3.2.3. Viability and Cytotoxicity
For Experiment C, cell viability was measured with the Cell Proliferation (XTT) Kit II (Roche,
Basel, Switzerland), according to the manufacturer’s protocol. Cells seeded in a 24-wells plate were
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incubated for 30 to 90 min with the XTT reagent mix. After incubation, 100 uL supernatant was
transferred to a 96-wells plate and absorbance was measured at 450 nm using an ELISA plate reader.
As a negative control, cells were treated with Triton X100 which resulted in total cell lysis.
Cytotoxicity was measured for each experiment with the Cytotoxicity Detection (LDH) Kit (Roche,
Basel, Switzerland), according to the manufacturer’s protocol. This kit measures the relative LDH
content present in the supernatant, which reflects cytotoxicity. Supernatant of the cells seeded in a
24-wells plate was transferred to a 96-wells plate and used to measure LDH content. Absorbance was
measured at 492 nm using an ELISA plate reader. As a positive control, cells were incubated with
Triton X100 which results in total cell lysis. Viability and cytotoxicity results are reported in Figures S1
and S2.
3.3. Statistics
All data are expressed as mean ± SEM. Statistical analyses were performed using GraphPad
Prism 5 (GraphPad Software Inc., La Jolla, California, USA). In Experiment A, different batches of
animals were used. Therefore, for all parameters, it was defined that combining the data was allowed,
meaning no interaction between groups and experiments was present. For all the in vivo experiments,
comparisons were made using an analysis of variance (ANOVA) with a Dunnett’s multiple comparison
test with the tumour-bearing group without nutritional supplementation as reference. Differences
were considered significant at a p-value < 0.05. Correlations were calculated and Pearson correlation
coefficients with a p-value < 0.05 were considered significant. For the in vitro experiments, comparisons
were made using an ANOVA with a Dunnett’s multiple comparison test with the vehicle control as
reference. Differences were considered significant at a p-value < 0.05.
4. Discussion
In line with our hypothesis and the available literature [14,15], tumour-bearing cachectic mice
showed hypercalcemia. Our data also demonstrate that plasma Ca2+ levels correlated negatively with
carcass mass and several organ masses. In addition, Ca2+ levels positively correlated with plasma
PGE-2 levels. Moreover, the nutritional combination reduced elevated plasma PGE-2 levels and PTHrP
levels in tumour tissue.
Only a few studies on the relation between fish oil, or its main components EPA and DHA,
and tumour-associated hypercalcemia have been reported in the literature. In a 1984 study, mice
bearing the prostaglandin producing HSDM1 fibrosarcoma, received menhaden fish oil high in EPA
(EPA:DHA ratio of 2.4:1). This intervention caused a reduction of plasma Ca2+ levels in tumour-bearing
mice [16]. Since hypercalcemia is related to bone mineral density and a reduction of bone mineral
density is a well-known feature of the C26 model, we also investigated the literature on reported
associations between fish oil treatment and bone mineral density. However, a systematic review onω3
fatty acids and osteoporosis concluded that clear conclusions are difficult to make, due to the small
number of studies and modest sample sizes [17]. In breast cancer survivors, high doses of EPA and
DHA were reported to reduce bone resorption [18]. Moreover, fish oil was found to prevent breast
cancer cell metastasis to bone and osteolytic lesions in a human mouse xenograft model [19].
In our study, decreased Ca2+ levels were only observed when leucine and fish oil were combined.
Interestingly, this suggests that leucine might have an additional favourable effect, but only in the
presence of fish oil. Leucine has been reported to influence insulin sensitivity of tissues and to increase
insulin release [20]. In addition, insulin seems to have an anti-phosphaturic effect [21]. It was reported
that in vivo administration of PTH induced a decline in tubular reabsorption of phosphate, which was
reversed by superimposition of an euglycemic hyperinsulinemia within the physiologic range [21].
The effect of leucine on hypercalcemia might, therefore, be explained by increased insulin release,
leading to increased renal absorption of phosphate.
In our study, dietary fish oil alone, or combined with leucine, reduced plasma PGE-2 levels.
Omega-3 PUFAs have been evaluated in various clinical studies for their immunomodulatory
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capacity [22]. Already after a week of intervention with a medical food high in protein, leucine,
fish oil, and specific oligosaccharides, plasma PGE-2 levels decreased in cancer patients receiving
radiotherapy [23]. The SNC tested in our study has also been shown to exert immunomodulatory effects
by reducing IL-6, TNF-α, IL-4, and PGE-2 plasma levels in the C26 model [24]. Another study reported
a decrease in PGE-2 levels in a small intestinal tumour of ApcMin/+ mice upon feeding with a high fat
diet rich in fish oil [25]. Eicosapentaenoic acid has been reported to decrease the pro-inflammatory
steady state by reducing the levels of TNF-α, IL-1β, IL-6, and IL-8 in serum or plasma [26]. Moreover,
EPA induces a shift in the pattern of prostaglandins produced by COX-2, from PGE-2 production with
arachidonic acid (AA) as substrate, to relatively more PGE-3 produced with EPA as substrate [27,28].
These results are all in line with our findings. However, there is also some conflicting evidence showing
that both DHA and EPA can stimulate PGE-2 production in both ScGT1 neuronal cells, raw 264.7
murine macrophages and human primary monocyte-derived macrophages [29,30].
The negative correlations between carcass weight and calcium levels, and those between muscle
weight and calcium indicate that the cachexia and hypercalcemia might be linked in our model. It is,
however, difficult to indicate to what extent they are related. With regards to muscle function, it
is, however, possible to correct for muscle mass. We revealed a high inverse correlation between
muscle function and hypercalcemia for maximal force, contraction velocity and relaxation velocity.
This correlation remained after correction for muscle mass, though with lower R values, indicating
that there seems to be a mass-independent compound in the relationship between calcium levels and
loss of muscle function as part of the cachexia syndrome.
Previous studies report that hypercalcemia in the C26 model is mediated by IL-6 and PTHrP [31].
We realize the limitations of this study as we were unable to measure either PTHrP or IL-6 in plasma.
From literature, we know that the same SNC is able to reduce IL-6 plasma levels in the C26 model [24].
Moreover, our results showed that the nutritional combination of fish oil and leucine reduced PTHrP
levels in the tumour. Elevation of PTHrP in malignancy is thought to be mediated by an increase
in COX-2 activity [8]. Therefore, the strong positive correlations of Ca2+ levels with PGE-2, a major
COX-2-mediated inflammatory mediator, might suggest that PTHrP is also involved in the induction
of hypercalcemia. To test this hypothesis, we performed a sequence of in vitro experiments.
Our results showed that among the nutrients tested in vivo, EPA and DHA seemed most potent
when a low number of cells was used, as seen in Experiment C. Interestingly, leucine did not have
any effect in vitro, whereas in vivo a combination of fish oil and leucine was needed to reduce Ca2+
and tumour PTHrP. This might be explained by acknowledging a synergistic effect of leucine when
combined with EPA/DHA compared to being administered alone on the reduction of Ca2+ and tumour
PTHrP. To test the potency in situations more similar to the in vivo situation, where C26 cells grow
in a solid tumour in the flank of the mice, we incubated a larger number of cells with DHA or EPA,
as seen in Experiment D. It should be mentioned that in vivo, the tumour consists of not only C26
cells but also stromal and inflammatory cells, which were not included in our in vitro studies. At
this higher confluency, where more cell–cell contact was present, only DHA proved able to reduce
PTHrP production. Previous research shows that ω3 PUFAs may exert anti-cancer activities on
several different cancer types [32]. Moreover, ω3 PUFAs have been found to be pro-apoptotic and
anti-proliferative in human colorectal cancer cell lines [33]. However, in our study, the effects on PTHrP
production were independent of cytotoxicity or viability. One could also argue that it is unlikely
that the proliferation of the cells changed, because XTT remained the same. PTHrP production in
C26 cells has previously been related to COX-2 activity [8], and DHA is known to be able to inhibit
COX-2 activity [12]. Therefore, our next step was to determine possible mediators of PTHrP by testing
involvement of COX-2, as seen in Experiment E. To this end, we incubated a large number of cells
with a specific COX-2 inhibitor CXB, and measured the effect of DHA on PGE-2 production and the
effect of CXB on PTHrP and PGE-2 production. Surprisingly, DHA was not able to reduce PGE-2
production, whereas CXB was. Moreover, PTHrP production did not change upon supplementation
with CXB. This was an unexpected result, since a different COX-2 inhibitor (NS-398) was able to reduce
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PTHrP production in C26 cells [8]. A possible explanation for the difference between our finding and
the literature is that in the NS-398 experiments, PTHrP production was only present in a spheroid
culture and not in monolayer cultures; in our experiments, PTHrP production was already visible in a
monolayer culture. From our in vitro experiments, we can conclude that DHA is possibly the most
potent component in reducing the PTHrP levels. The reduction in PTHrP production was most likely
not mediated by COX-2, leaving the mechanism of action of DHA still an open question.
Bone health and calcium homeostasis are important factors affected by malignancy. In this study,
we showed that tumour-induced hypercalcemia is highly correlated with several cachexia related
outcomes. We also showed that a nutritional intervention high in leucine and fish oil can reduce the
detrimental effects of the tumour on calcium homeostasis in a tumour-bearing C26 mouse model.
This is clinically relevant, since calcium homeostasis can have a large impact on the daily life of patients.
In a study of 686 multiple myeloma patients, serum calcium levels were associated with quality of life
(QOL) scores, appetite loss, nausea/vomiting, physical functioning (p < 0.001), cognitive functioning
(p = 0.001), and the scores for fatigue and pain (p < 0.001) [5]. Moreover, we elucidated possible
mechanisms behind the beneficial effects of fish oil supplementation on hypercalcemia. The ω3 PUFA
DHA, one of the potent components found in vivo, reduced PTHrP production of C26 cells in vitro.
A reduction in PTHrP is important, independent of its effects on calcium homeostasis and bone health,
since PTHrP is also related to an increase in adipose tissue browning and muscle wasting [9,34]. Further
research in the mechanism involved in the beneficial effects of ω3 PUFA is needed to further optimize
nutritional support for cancer patients.
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